生存结果用于验证美国癌症联合委员会附录癌症分期系统第9版。

IF 503.1 1区 医学 Q1 ONCOLOGY
Lauren M. Janczewski MD, MS, Amanda E. Browner MS, Joseph H. Cotler PhD, Heidi Nelson MD, Sanjay Kakar MD, Norman J. Carr MBBS, Nader N. Hanna MD, Andreana N. Holowatyj PhD, MS, Richard M. Goldberg MD, M. Kay Washington MD, PhD, Elliot A. Asare MD, MS, Michael J. Overman MD, the American Joint Committee on Cancer Expert Panel on Cancers for the Lower Gastrointestinal Appendix Disease Site
{"title":"生存结果用于验证美国癌症联合委员会附录癌症分期系统第9版。","authors":"Lauren M. Janczewski MD, MS,&nbsp;Amanda E. Browner MS,&nbsp;Joseph H. Cotler PhD,&nbsp;Heidi Nelson MD,&nbsp;Sanjay Kakar MD,&nbsp;Norman J. Carr MBBS,&nbsp;Nader N. Hanna MD,&nbsp;Andreana N. Holowatyj PhD, MS,&nbsp;Richard M. Goldberg MD,&nbsp;M. Kay Washington MD, PhD,&nbsp;Elliot A. Asare MD, MS,&nbsp;Michael J. Overman MD,&nbsp;the American Joint Committee on Cancer Expert Panel on Cancers for the Lower Gastrointestinal Appendix Disease Site","doi":"10.3322/caac.21806","DOIUrl":null,"url":null,"abstract":"<p>The standard for cancer staging in the United States for all cancer sites, including primary carcinomas of the appendix, is the American Joint Committee on Cancer (AJCC) staging system. AJCC staging criteria undergo periodic revisions, led by a panel of site-specific experts, to maintain contemporary staging definitions through the evaluation of new evidence. Since its last revision, the AJCC has restructured its processes to include prospectively collected data because large data sets have become increasingly robust and available over time. Thus survival analyses using AJCC eighth edition staging criteria were used to inform stage group revisions in the version 9 AJCC staging system, including appendiceal cancer. Although the current AJCC staging definitions were maintained for appendiceal cancer, incorporating survival analysis into the version 9 staging system provided unique insight into the clinical challenges in staging rare malignancies. This article highlights the critical clinical components of the now published version 9 AJCC staging system for appendix cancer, which (1) justified the separation of three different histologies (non-mucinous, mucinous, signet-ring cell) in terms of prognostic variance, (2) demonstrated the clinical implications and challenges in staging heterogeneous and rare tumors, and (3) emphasized the influence of data limitations on survival analysis for low-grade appendiceal mucinous neoplasms.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"73 6","pages":"590-596"},"PeriodicalIF":503.1000,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer\",\"authors\":\"Lauren M. Janczewski MD, MS,&nbsp;Amanda E. Browner MS,&nbsp;Joseph H. Cotler PhD,&nbsp;Heidi Nelson MD,&nbsp;Sanjay Kakar MD,&nbsp;Norman J. Carr MBBS,&nbsp;Nader N. Hanna MD,&nbsp;Andreana N. Holowatyj PhD, MS,&nbsp;Richard M. Goldberg MD,&nbsp;M. Kay Washington MD, PhD,&nbsp;Elliot A. Asare MD, MS,&nbsp;Michael J. Overman MD,&nbsp;the American Joint Committee on Cancer Expert Panel on Cancers for the Lower Gastrointestinal Appendix Disease Site\",\"doi\":\"10.3322/caac.21806\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The standard for cancer staging in the United States for all cancer sites, including primary carcinomas of the appendix, is the American Joint Committee on Cancer (AJCC) staging system. AJCC staging criteria undergo periodic revisions, led by a panel of site-specific experts, to maintain contemporary staging definitions through the evaluation of new evidence. Since its last revision, the AJCC has restructured its processes to include prospectively collected data because large data sets have become increasingly robust and available over time. Thus survival analyses using AJCC eighth edition staging criteria were used to inform stage group revisions in the version 9 AJCC staging system, including appendiceal cancer. Although the current AJCC staging definitions were maintained for appendiceal cancer, incorporating survival analysis into the version 9 staging system provided unique insight into the clinical challenges in staging rare malignancies. This article highlights the critical clinical components of the now published version 9 AJCC staging system for appendix cancer, which (1) justified the separation of three different histologies (non-mucinous, mucinous, signet-ring cell) in terms of prognostic variance, (2) demonstrated the clinical implications and challenges in staging heterogeneous and rare tumors, and (3) emphasized the influence of data limitations on survival analysis for low-grade appendiceal mucinous neoplasms.</p>\",\"PeriodicalId\":137,\"journal\":{\"name\":\"CA: A Cancer Journal for Clinicians\",\"volume\":\"73 6\",\"pages\":\"590-596\"},\"PeriodicalIF\":503.1000,\"publicationDate\":\"2023-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CA: A Cancer Journal for Clinicians\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.3322/caac.21806\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21806","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

美国所有癌症部位(包括原发性阑尾癌)的癌症分期标准是美国癌症联合委员会(AJCC)分期系统。AJCC分期标准在特定地点专家小组的领导下进行定期修订,以通过评估新证据来维持当代分期定义。自上次修订以来,AJCC对其流程进行了重组,以包括前瞻性收集的数据,因为随着时间的推移,大型数据集变得越来越强大和可用。因此,使用AJCC第八版分期标准的生存率分析用于告知第9版AJCC分期系统中的分期组修订,包括阑尾癌症。尽管目前的AJCC分期定义对附件癌症保持不变,但将生存分析纳入第9版分期系统为罕见恶性肿瘤分期的临床挑战提供了独特的见解。这篇文章强调了现已发表的附录癌症第9版AJCC分期系统的关键临床组成部分,该系统(1)从预后变化的角度证明了三种不同组织(非黏液性、黏液性、印戒细胞)的分离,(2)证明了异质性和罕见肿瘤分期的临床意义和挑战,以及(3)强调了数据限制对低级别阑尾粘液性肿瘤生存分析的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer

Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer

The standard for cancer staging in the United States for all cancer sites, including primary carcinomas of the appendix, is the American Joint Committee on Cancer (AJCC) staging system. AJCC staging criteria undergo periodic revisions, led by a panel of site-specific experts, to maintain contemporary staging definitions through the evaluation of new evidence. Since its last revision, the AJCC has restructured its processes to include prospectively collected data because large data sets have become increasingly robust and available over time. Thus survival analyses using AJCC eighth edition staging criteria were used to inform stage group revisions in the version 9 AJCC staging system, including appendiceal cancer. Although the current AJCC staging definitions were maintained for appendiceal cancer, incorporating survival analysis into the version 9 staging system provided unique insight into the clinical challenges in staging rare malignancies. This article highlights the critical clinical components of the now published version 9 AJCC staging system for appendix cancer, which (1) justified the separation of three different histologies (non-mucinous, mucinous, signet-ring cell) in terms of prognostic variance, (2) demonstrated the clinical implications and challenges in staging heterogeneous and rare tumors, and (3) emphasized the influence of data limitations on survival analysis for low-grade appendiceal mucinous neoplasms.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
873.20
自引率
0.10%
发文量
51
审稿时长
1 months
期刊介绍: CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信